Midterml Exam:l NRl 568l NR568l Latestl

Midterml Exam:l NRl 568/l NR568l (Latestl

2026/l 2027l Update)l Advancedl Pharmacologyl forl thel Adult-Gerontologyl Primaryl Carel Nursel Practitionerl Reviewl |Q/Al |l Gradel A|l 100%l Correctl (Verifiedl Answers)l -Chamberlain

Q:l sulfonamidel drugs/moa

Answer:

ol Drugsl :l sulfacetamide,l sulfadiazine,l sulfamethoxazole-trimethopriml (TMP/SMX) ol MOA:l Inhibitl synthesisl ofl folatel whichl isl necessaryl forl RNA&l DNA ·l (+l /l -,l Broadl spectrum)l CATl Dl inl pregnancy,l orl underl 2l monthsl ofl age,l lastl trimesterl ofl pregnancy

Q:l sulfonamidel usel /l se

Answer:

ol Use:

§l TMP/SMX:l Bactriml -l uncomplicatedl bacteriall cystitisl (UTI)l andl pyelonephritis §l Chlamydia,l pneumonial inl immunocompromisedl pt,l malaria,l ulcerativel colitis,l burns malaria,l toxoplasmosis

ol Sidel effects:l Hypersensitivity

Hematologicl anemial withl G6PDl deficiencyl (Blackl orl Mediterranean) Nephrotoxicityl (watchl bun,l cr) Carefull withl peoplel thatl takel warfarinl (watchl INR)

Q:l Whichl antibioticl isl typicallyl thel firstl choicel forl treatingl uncomplicatedl UTIsl inl women?

Answer: 1 / 4

Trimethoprim-Sulfamethoxazole

Q:l Rifamycinsl moal (rifabutin/rifampin)

Answer:

inhibitl mycobacteriall DNA-dependentl RNAl polymerase,l suppressingl proteinl synthesis.l Theyl arel usedl primarilyl tol treatl tuberculosisl andl preventl disseminatedl Mycobacteriuml aviuml complexl (MAC)l inl HIV-infectedl clients.

Q:l Rifamycinsl sidel effect

Answer:

mayl causel orange-redl discolorationl ofl bodilyl fluidsl andl hepatotoxicity.l Thesel drugsl havel interactionsl withl numerousl otherl drugsl duel tol potentl enzymel inductionl andl requirel carefull monitoringl ofl co-administeredl medications.

Q:l tetracyclinel (doxycycline,l minocycline)l moa

Answer:

ol MOA:l inhibitl bacteriall proteinl synthesisl byl bindingl tol 30Sl ribosomall subunits

ol PK/PD:l PO,l IV,l topical

Q:l tetracyclinel pk/pd,l pregnancy

Answer:

+l /l -l broadl spectruml extendedl halfl life

ol PK/PD:l PO,l IV,l topical

Pregnancy**:l Categoryl D—contraindicatedl (riskl ofl toothl discoloration,l bonel growthl inhibitionl inl fetus,l andl maternall hepatotoxicity,l especiallyl inl 2nd/3rdl trimesters).-l **Breastfeeding**:l Contraindicated—transfersl intol breastl milk,l canl causel toothl discolorationl andl bonel growthl inhibitionl inl thel infant

Q:l tetracyclinel (doxycycline)l sidel effects 2 / 4

Answer:

Affectl calcificationl ofl bonesl andl teethl (dol notl usel inl childrenl

Drugl interactions:l Orall Contraceptivel Pills

Photosensitivity GI,l Renal

Q:l tetracyclinel use

Answer:

ol Use:

§l Rickettsiall infections §l Ehrlichiosis §l Anaplasmosis §l Leptospirosis, §l Chlamydia,l Pelvicl inflammatoryl disease,l Syphilis §l Lymel diseasel Borelial burgdorferil (100l mgl orallyl (PO)l twicel dailyl (BID)l forl 10-21l daysl forl infection.) §l Legionnaire'sl disease

Q:l glycopeptidel (vancomycin)l moa

Answer:

:l Vancomycinl inhibitsl celll walll synthesis,l promotingl bacteriall lysisl andl death.l Itl disruptsl thel celll walll byl bindingl tol thel moleculesl orl precursorsl forl celll walll biosynthesisl (treatsl MRSA) POl orl IVl -l adminl IVl slowl preventl redmanl syndrome

Q:l glycopeptidel (Vancomycin)l use

Answer:

Clostridiuml difficilel colitisl (orall vancomycin),l MRSA,l reservedl forl seriousl infections ·l 10l daysl ofl orall vancomycinl 125l mgl pol QIDl orl fidaxomicinl (Dificid)l 200l mgl POl BIDl xl 10l daysl (ifl severe,l longerl treatment,l addl onl metronidazole)

• / 4

Q:l glycopeptidel (vancomycin)l adversel effects

Answer:

BB:l nephrotoxicity,l ototoxicity,l andl

"Redl Manl Syndrome."l Monitoringl ofl drugl levelsl andl renall functionl isl necessary,l especiallyl whenl administeredl intravenously.l IVl Adminl slow immunel mediatedl thrombocytopenia -l **Pregnancy**:l Categoryl C—usel withl cautionl (limitedl data,l butl oftenl usedl forl seriousl infectionsl likel MRSAl inl pregnancy;l monitorl forl fetall ototoxicity).-l **Breastfeeding**:l Compatible—minimall transferl intol breastl milkl withl orall use,l generallyl safe;l monitorl infantl forl GIl upsetl withl IVl use.

Q:l Lincosamidesl (Clindamycin)l moa

Answer:

MOA:l Inhibitsl proteinl synthesisl atl thel 50Sl subunitl ofl bacteriall ribosome narrowl tol moderatel spectrum ol Doesn'tl crossl BBB,l -l hepaticl elimination

Q:l lincosamidel (clindamycin)l use

Answer:

ol Use:l graml +l anaerobes,l cocci,l s.l aureus,l s.l pneumonia,l skin,l softl tissuel -l dentall abscess

ol Sidel effects:l Blackl Boxl C.Diffl risk

Pregnancyl catl B,l canl usel inl breastfeedingl butl monitorl GIl upsetl ofl infant

Q:l daptomycinl moa

Answer:

Formsl al channell inl bacteriall celll membranel causingl lossl ofl intracellularl ionsl likel K,l inhibitsl synthesisl ofl DNA,l RNA IVl only graml +l bacterialcidal

• / 4